Tue. 27 Feb 2024, 4:10pm ET
Benzinga
Earnings, Earnings Misses, News
Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(0.97) by 42.27 percent. The company reported quarterly sales of $1.67 million which missed the analyst consensus estimate of $10.77 million by 84.48 percent. This is a 14.56 percent decrease over sales of $1.96 million the same period last year.